

ORAL PRESENTATION

Open Access

# The PTEN pathway in Tregs functions as a critical driver of the immunosuppressive tumor microenvironment and tolerance to apoptotic cells

Madhav Sharma<sup>1</sup>, Rahul Shinde<sup>1</sup>, Tracy McGaha<sup>1</sup>, Lei Huang<sup>1</sup>, Rikke Holmgaard<sup>2</sup>, Jedd Wolchok<sup>2</sup>, Mario Mautino<sup>3</sup>, Esteban Celis<sup>1</sup>, Arlene Sharpe<sup>4</sup>, Loise Francisco<sup>4</sup>, Jonathan Powell<sup>5</sup>, Hideo Yagita<sup>6</sup>, Andrew Mellor<sup>1</sup>, Bruce Blazar<sup>7</sup>, David Munn<sup>8\*</sup>

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

National Harbor, MD, USA. 4-8 November 2015

The tumor microenvironment is profoundly immunosuppressive, but exactly how this is coordinated and maintained remains poorly understood. We show that multiple transplantable and autochthonous mouse tumors actively elicit a population of highly suppressive regulatory T cells (Tregs) expressing the lipid phosphatase PTEN. These PTEN<sup>+</sup> Tregs co-expressed PD-1, Foxp3, and high levels of Eos (*Ikrzf4*). PTEN signaling acted to stabilize tumor-associated Tregs, maintaining their suppressor activity and preventing conversion into pro-inflammatory effector cells (“ex-Tregs”) in the face of inflammation. Mice with a targeted deletion of PTEN in Tregs (PTEN-Treg-KO mice) were healthy and fertile when young, but gradually developed lupus-like autoimmunity as they aged. Tumors implanted in young, healthy PTEN-Treg-KO mice were unable to create the normal immunosuppressive tumor microenvironment; instead, tumors were constitutively immunogenic, chronically inflamed, and could barely grow. In wild-type mice with large, pre-established tumors, pharmacologic inhibition of PTEN during the period following chemotherapy or adoptive immunotherapy caused a profound reconfiguration of the tumor microenvironment. The normally suppressive intratumoral Tregs became destabilized, and rapidly reprogrammed into pro-inflammatory “ex-Tregs” expressing IL-2, IL-17 and CD40L. The dominant APCs in the tumor changed

from tolerogenic DCs expressing high levels of PD-L1, and were replaced by inflammatory myeloid DCs expressing high levels of CD86, MHC class II, IL-6 and IL-12. CD8<sup>+</sup> effector T cells in the tumor, which had previously been unresponsive and PD-1<sup>+</sup> (exhausted), became activated and expressed IFN $\gamma$  and GzmB, and mediated tumor regression. Pharmacologic inhibition of PTEN was highly synergistic with conventional chemotherapy, allowing a single modest, normally ineffective dose of chemotherapy to trigger rapid tumor involution. This synergy was strictly immune-mediated, and was lost in the absence of host CD8<sup>+</sup> T cells. In mice without tumors, identical PTEN<sup>+</sup> Tregs were physiologically elicited by exposure to apoptotic cells; and PTEN-Treg-KO mice rapidly developed lupus-like autoimmunity when repeatedly challenged with apoptotic cells. The induction of PTEN<sup>+</sup> Tregs by apoptotic cells was driven by indoleamine 2,3-dioxygenase (IDO) in the host, and was blocked by pharmacologic inhibition of IDO. Taken together, these data identify the PTEN pathway in Tregs as a potent immunosuppressive mechanism in tumors. PTEN<sup>+</sup> Tregs controlled the downstream activation of inflammatory DCs and effector CD8<sup>+</sup> T cells, and were part of the fundamental mechanism of tolerance to apoptotic cells. The PTEN pathway thus represents a potent, centrally-positioned immunosuppressive mechanism in tumors, which is amenable to pharmacologic inhibition and shows

<sup>8</sup>Georgia Regents University Cancer Center, Augusta, GA, USA  
Full list of author information is available at the end of the article

synergy with both adoptive immunotherapy and conventional chemotherapy.

#### Authors' details

<sup>1</sup>Georgia Regents University, Augusta, GA, USA. <sup>2</sup>Memorial Sloan-Kettering Cancer Center, New York, NY, USA. <sup>3</sup>NewLink Genetics, Inc., Ames, IA, USA. <sup>4</sup>Harvard Medical School, Boston, MA, USA. <sup>5</sup>Johns Hopkins University School of Medicine, Baltimore, MD, USA. <sup>6</sup>Juntendo University School of Medicine, Tokyo, Japan. <sup>7</sup>University of Minnesota, Minneapolis, MN, USA. <sup>8</sup>Georgia Regents University Cancer Center, Augusta, GA, USA.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-O19

**Cite this article as:** Sharma *et al.*: The PTEN pathway in Tregs functions as a critical driver of the immunosuppressive tumor microenvironment and tolerance to apoptotic cells. *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):O19.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

